A pivotal joint workshop convened by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on September 25, 2026, aimed to delineate and streamline the regulatory pathways for botanical drugs in both major global markets. Held at the EMA headquarters in Amsterdam, the early-morning session, which necessitated an inconvenient start for North American attendees, nevertheless drew a remarkable turnout of over 1,000 participants, underscoring the burgeoning global interest in plant-derived therapeutics. The comprehensive agenda featured high-level administrators from both regulatory bodies, alongside crucial input from influential stakeholder organizations, including the Reagan Udall Foundation for the FDA, the Botanicals Safety Consortium, the American Botanical Council (ABC), and the American Herbal Products Association (AHPA). The workshop’s primary objective was to identify commonalities, highlight divergences, and propose actionable strategies to facilitate the market entry of botanical drug products, a category experiencing significant growth and increasing consumer demand.
The Ascending Trajectory of Herbal and Botanical Therapeutics
The day’s proceedings commenced with an in-depth examination of the escalating demand and paramount importance of botanical drug products within the broader healthcare landscape. Stefan Gafner, Chief Science Officer at the American Botanical Council (ABC), presented compelling data illustrating the rapid expansion of herbal product sales in the United States. His analysis provided a critical counterpoint to the regulatory challenges, highlighting that botanical health products submitted and regulated under the European Union’s established botanical drug framework demonstrate a significantly lower risk of adulteration compared to similar products marketed as dietary supplements in the U.S., where adulteration rates have been a persistent concern. This distinction is crucial for public health and consumer confidence.
Further insights into the practical implementation of botanical drug utilization were provided by Jorge Batista, representing a collective of community pharmacies across Europe. Batista elaborated on the integral role pharmacists play in the safe and effective administration of botanical drugs within European member states, emphasizing their expertise in patient counseling and monitoring. From a consumer advocacy perspective, Dominique Hamerlijnck of the European Lung Foundation underscored a significant hurdle: the current difficulty consumers face in accessing comprehensive information regarding botanical drugs, particularly potential interactions with other medications. While this vital data exists, Hamerlijnck noted, it is often fragmented across numerous websites and frequently cataloged under complex Latin binomial species designations, rendering it obscure and challenging for the average patient to locate and understand. This lack of accessible information not only hinders informed decision-making but also poses a potential risk to patient safety.
Navigating the Labyrinth of Regulatory Frameworks
The core of the workshop then shifted to the intricate regulatory architectures governing botanical drugs in the U.S. and the E.U. Cassandra Taylor from the FDA provided a detailed overview of the U.S. regulatory structure, which is fundamentally rooted in the Federal Food, Drug, and Cosmetic (FD&C) Act and further refined through a complex web of regulations and guidance documents. This framework typically necessitates extensive preclinical and clinical data to establish safety and efficacy for specific indications.
In contrast, Carmen Purdel, Chair of the EMA’s Committee for Herbal Medicinal Products (HMPC), outlined the E.U.’s more "bottom-up" approach. This model leverages a substantial body of existing safety information derived from products already authorized and on the market within E.U. member states, often under various traditional herbal designations. The E.U. framework also allows for flexibility based on the applicant’s market objectives, differentiating between seeking authorization for the entire E.U. market or for specific individual countries. This nuanced approach, while potentially more accessible for certain products, has also led to a mosaic of national regulations within the Union.
A compelling case study illustrating the comparative regulatory demands was presented by Charles Wu of the FDA and Jacqueline Wiesner of the EMA’s HMPC, focusing on FILSUVEZ, a drug derived from a birch extract and utilized for the treatment of a rare skin condition. The extract contains a complex mixture of birch triterpenes. Wu’s presentation underscored the FDA’s rigorous emphasis on the comprehensive characterization of the active substance and the stringent proof required for manufacturing processes that ensure minimal batch-to-batch variability. The EMA, on the other hand, required standardization to only one of the key terpenes. This divergence in standardization requirements highlights a fundamental difference in the level of detailed chemical and manufacturing control demanded by each agency, with the FDA’s approach generally necessitating a deeper scientific understanding and control over the entire product composition.
The Economic Chasm: Cost as a Significant Barrier to Entry
While the FILSUVEZ case study offered valuable comparative insights, it implicitly touched upon a critical, yet underexplored, issue: the substantial economic disparity in the regulatory process. Anecdotal evidence and industry reports suggest that obtaining FDA approval for a botanical drug can be as much as ten times more costly and significantly more challenging than navigating the E.U. system. Over several decades, only a handful of botanical drugs have received approval in the U.S. Many submissions have reportedly faltered due to the inability to conclusively demonstrate quality parameters to the FDA’s exacting satisfaction, particularly concerning reproducible manufacturing and detailed characterization of the active constituents. This economic hurdle disproportionately impacts smaller companies and researchers, potentially stifling innovation in the botanical drug sector within the United States.
Stakeholder Dialogue and Future Considerations
The workshop culminated in a dynamic panel discussion featuring key representatives from industry and regulatory support organizations. Angela Mueller and Christelle Anquez-Traxler of the Association of the European Self-Care Industry (AESGP), Holly Johnson from the American Herbal Products Association (AHPA), and Susan Winckler of the Reagan Udall Foundation for the FDA engaged in a robust exchange of ideas regarding potential improvements.
One prominent suggestion explored was the creation of a distinct, intermediate regulatory category in the U.S. This hypothetical category would bridge the gap between conventional pharmaceuticals and dietary supplements, specifically designed to accommodate botanical drugs. However, Winckler pointed out that such a legislative endeavor would necessitate an amendment to the FD&C Act, a prospect widely viewed as politically challenging and unlikely in the current legislative climate.
Another frequently reiterated suggestion, resonating across various sessions, was the imperative for more targeted research initiatives and increased public funding to support such endeavors. This call for enhanced research infrastructure and financial backing is a recurring theme in discussions aimed at advancing the scientific understanding and regulatory viability of botanical therapeutics.
An Expert’s Perspective on the Evolving Landscape
Roy Upton, founder of the American Herbal Pharmacopoeia, a prominent organization dedicated to the standardization and research of medicinal herbs, has been meticulously observing the renewed momentum behind botanical drug development. His keen interest lies in identifying any potential unintended consequences for herbal products currently marketed as dietary supplements in the U.S. In the wake of the FDA/EMA workshop, Upton disseminated a concise yet impactful written statement:
"The workshop demonstrated growing international interest in the development and regulation of botanical medicinal products and highlighted both significant opportunities and substantial challenges," Upton stated. "The central themes included the importance of safety, efficacy, quality, pharmacovigilance, real-world evidence, appropriate regulatory pathways, education, transparency, and collaboration. The discussion also underscored the value of learning from existing regulatory experience, particularly the more than two decades of experience within the European system, while recognizing the distinct statutory and regulatory environment in the United States."
Upton’s commentary emphasizes the critical need for a balanced approach that leverages international best practices while respecting the unique legal and regulatory framework of the United States. His focus on collaboration and transparency underscores the collaborative spirit required to advance the field.
Implications for the Future of Botanical Therapeutics
The joint FDA/EMA workshop represents a significant step forward in fostering a more harmonized and accessible regulatory environment for botanical drugs. The acknowledged challenges, particularly the cost and complexity of the U.S. approval process, coupled with the consumer-facing issue of information accessibility, necessitate continued dialogue and concrete action.
The growing consumer demand for natural health products, as evidenced by the data presented by ABC, suggests that the market for botanical therapeutics will continue its upward trajectory. For this growth to be sustainable and safe, regulatory bodies, industry stakeholders, and consumer advocacy groups must work collaboratively. The potential for a distinct regulatory pathway in the U.S., though legislatively challenging, remains a concept worth exploring as a means to de-risk and de-monetize the development process for these promising natural medicines.
Furthermore, the insights gained from the E.U.’s established framework, particularly regarding the utilization of historical safety data and the role of community pharmacists, offer valuable lessons for U.S. policymakers and regulators. The commitment to making a recording of the session available to those unable to attend signals a dedication to transparency and broad dissemination of the crucial information discussed. As the understanding and application of botanical drugs evolve, continued collaboration between international regulatory agencies and robust engagement with all stakeholders will be paramount in ensuring that these valuable natural products can reach patients safely and effectively.
This article was written by Hank Schultz, Senior Editor at SupplySide Supplement Journal.
